CNSX:BUX Biomark Diagnostics (BUX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free BUX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume11,500 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biomark Diagnostics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Biomark Diagnostics Stock (CNSX:BUX)BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. BUX Stock News HeadlinesApril 20, 2024 | finance.yahoo.comBlackRock Allocation Target Shrs Ser A (BATAX)April 18, 2024 | finance.yahoo.comBioMark Announces Warrant Extension and Granting of OptionsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | finance.yahoo.comBioMark to Advance Development of Cancer Treatment for GlioblastomaFebruary 28, 2024 | finance.yahoo.comBioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved CommunitiesFebruary 26, 2024 | finance.yahoo.comTheresa Peterson Joins Biomark's Advisory TeamFebruary 20, 2024 | fortune.comQuest DiagnosticsDecember 29, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Announces Closing of $1.9 Million Non-Brokered Private PlacementApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 29, 2023 | finance.yahoo.comBioMark Announces Closing of $1.9 Million Non-Brokered Private PlacementDecember 4, 2023 | markets.businessinsider.comBioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy AssayNovember 28, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise TermNovember 14, 2023 | finance.yahoo.comBioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization InitiativesOctober 24, 2023 | finance.yahoo.comBioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer SymposiumAugust 30, 2023 | finance.yahoo.comBioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory TeamAugust 8, 2023 | finance.yahoo.comJapan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy AssayJuly 25, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate UpdateJuly 25, 2023 | finance.yahoo.comBioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate UpdateJuly 17, 2023 | mirror.co.ukGary Lineker and ex-stepdaughter Ella Bux put on a smiley display at WimbledonJune 5, 2023 | finance.yahoo.comBioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual MeetingMay 31, 2023 | finance.yahoo.comBioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy AssayMay 5, 2023 | marketwatch.comLiver Cancer Diagnostic Tests Market to Witness Huge Growth with Abbott Diagnostics, Abcodia, BioMark Technologies, AXO Science SASMay 3, 2023 | markets.businessinsider.comBioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023April 10, 2023 | msn.comCanadian Cancer Diagnostic Company BioMark Working On Early Lung Detection AssayMarch 16, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine TumorsMarch 16, 2023 | finance.yahoo.comBioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine TumorsMarch 1, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Provides Third Quarter Operational Update and 2023 OutlookSee More Headlines Receive BUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomark Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolCNSX:BUX CUSIPN/A CIKN/A Webwww.biomarkdiagnostics.com Phone604-370-0779FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Rashid Ahmed Maula Bux B.Sc.MBA, Founder, CEO, Pres & DirectorMs. Guoyu Huang MBAChief Financial OfficerMr. Brian Kai-Ming Cheng B.Sc.M.Sc, M.Sc., Chief Technical Officer & Independent DirectorDr. Jeff Haince Ph.D.GM & Chief Scientific OfficerNeal KaplanChief Financial Officer of USDr. Daniel SitarPrincipal Scientific AdvisorMore ExecutivesKey CompetitorsCharles River Laboratories InternationalCNSX:CRL45525 (CUR.TO)TSE:CURAbattis BioceuticalsCNSX:ATTAgraflora Organics InternationalCNSX:AGRAAmplify Alternative Harvest ETFCNSX:MJView All CompetitorsInsidersRashid Ahmed Maula BuxBought 10,700 shares on 4/18/2024Total: $2,921.10 ($0.27/share)Guoyu HuangBought 8,500 shares on 4/18/2024Total: $2,252.50 ($0.27/share)Guoyu HuangBought 5,000 shares on 4/11/2024Total: $1,400.00 ($0.28/share)Rashid Ahmed Maula BuxBought 2,600 shares on 4/11/2024Total: $780.00 ($0.30/share)Rashid Ahmed Maula BuxBought 1,100 shares on 3/15/2024Total: $330.00 ($0.30/share) BUX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Biomark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomark Diagnostics investors own include Stantec (STN) and IQE (IQE). How do I buy shares of Biomark Diagnostics? Shares of BUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (CNSX:BUX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomark Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
